Anebulo Pharmaceuticals
ANEB
ANEB was delisted on the 27th of February, 2026.
18 hedge funds and large institutions have $29.4M invested in Anebulo Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
20% more funds holding
Funds holding: 15 → 18 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
21% less capital invested
Capital invested by funds: $37.3M → $29.4M (-$7.91M)
32% less ownership
Funds ownership: 87.04% → 55.05% (-32%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$234K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$168K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$74.3K |
| 4 |
Goldman Sachs
New York
|
+$70.5K |
| 5 |
HF
HRT Financial
New York
|
+$34.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
LVW Advisors
Pittsford,
New York
|
-$416K |
| 2 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
-$100K |
| 3 |
Morgan Stanley
New York
|
-$30.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$35 |
| 5 |
JP Morgan Chase
New York
|
-$1 |
ANEB Hedge Fund Activity: Q1 2025 in Review
18 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Anebulo Pharmaceuticals (ANEB) for Q1 2025, worth a combined $29.4M — down 21% from $37.3M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ANEB positions and 1 closed out — a net gain of 3 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $234K. The largest seller was LVW Advisors, cutting an estimated $416K.
- 18 institutional investors held Anebulo Pharmaceuticals (ANEB) as of Q1 2025, up from 15 in Q4 2024.
- Funds reported $29.4M of Anebulo Pharmaceuticals stock for Q1 2025, down 21% quarter-over-quarter.
- 4 funds opened new Anebulo Pharmaceuticals positions in Q1 2025 and 1 closed out, a net change of +3 holders.
- The largest Anebulo Pharmaceuticals buyer in Q1 2025 was Millennium Management, an estimated $234K added.
- The largest Anebulo Pharmaceuticals seller in Q1 2025 was LVW Advisors, an estimated $416K sold.
Based on aggregated 13F filings for Q1 2025.